Village Farms International And 2 Other Penny Stocks Worth Watching

The market has shown robust performance, with a 2.7% increase over the last week and a 21% rise in the past year, while earnings are expected to grow by 17% annually. In light of these conditions, investors may find value in exploring penny stocks—an older term that still signifies potential within smaller or emerging companies. By focusing on those with solid financials and growth potential, investors can uncover opportunities for both stability and upside in this unique segment of the market.

We're going to check out a few of the best picks from our screener tool.

Village Farms International (VFF)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Village Farms International, Inc. operates in North America and the Netherlands, focusing on the production, marketing, and distribution of greenhouse-grown tomatoes, bell peppers, and cucumbers with a market cap of $237.72 million.

Operations: The company's revenue from its Canadian cannabis segment is $174.23 million.

Market Cap: $237.72M

Village Farms International has shown resilience in the penny stock arena, with its market cap at US$237.72 million and a focus on greenhouse-grown produce and cannabis. The company recently reported second-quarter sales of US$63.98 million, up from US$59.9 million the previous year, though net income decreased to US$7.15 million from US$26.5 million a year ago due to various factors including product expansion costs like Super Toast Bites in Canada’s growing edibles market. Despite low return on equity at 8.5%, Village Farms maintains strong financials with short-term assets exceeding liabilities and reduced debt levels over five years, reflecting prudent fiscal management amidst industry challenges.

• Navigate through the intricacies of Village Farms International with our comprehensive balance sheet health report here.
• Review our growth performance report to gain insights into Village Farms International's future.

NovaBridge Biosciences (NBP)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: NovaBridge Biosciences is a biotechnology company focused on researching and developing immuno-oncology agents for cancer treatment in the United States, with a market cap of $202.38 million.

Operations: There are no revenue segments reported for NovaBridge Biosciences.

Market Cap: $202.38M

NovaBridge Biosciences, with a market cap of US$202.38 million, remains pre-revenue and debt-free, focusing on developing immuno-oncology agents. The company recently appointed Dr. Srishti Gupta as CEO to steer strategic growth and partnerships. NovaBridge's lead candidate, givastomig, received FDA Fast Track Designation for gastric cancer treatment, highlighting its potential in addressing unmet medical needs. Despite being unprofitable with a negative return on equity of -38.25%, the company has reduced losses by 17.4% annually over five years and maintains sufficient cash runway exceeding three years based on current free cash flow levels.

• Dive into the specifics of NovaBridge Biosciences here with our thorough balance sheet health report.
• Gain insights into NovaBridge Biosciences' future direction by reviewing our growth report.

Quanterix (QTRX)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Quanterix Corporation is a life sciences company operating in North America, Europe, the Middle East, Africa, and the Asia Pacific regions with a market cap of $189.84 million.

Operations: The company generates revenue primarily from its Diagnostic Kits and Equipment segment, which amounted to $144.98 million.

Market Cap: $189.84M

Quanterix Corporation, with a market cap of US$189.84 million, is navigating the challenges of being unprofitable while maintaining a debt-free status and stable cash runway exceeding one year. Recent revenue growth to US$69.32 million for the first half of 2026 reflects progress in its Diagnostic Kits and Equipment segment, although losses have widened to US$66.48 million over the same period. The company is advancing Alzheimer's diagnostics with LucentAD Complete, supported by Anthem Blue Cross coverage, enhancing clinical adoption prospects despite recent index exclusions and management transitions indicating strategic shifts in leadership focus.

• Click here and access our complete financial health analysis report to understand the dynamics of Quanterix.
• Examine Quanterix's earnings growth report to understand how analysts expect it to perform.

Seize The Opportunity

• Click here to access our complete index of 327 US Penny Stocks.
• Searching for a Fresh Perspective? Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com